Caris Life Sciences Q3 2026: Record Volume Drives a Double Beat
As seen on the 24/7 Wall St. homepage on November 4, 2026.
Caris raised full-year revenue guidance to $1.04 billion to $1.05 billion after clinical case volume rose about 21% to roughly 61,500, with both lines ahead of expectations. Operating expenses jumped 42% and free cash flow swung to negative $39.7 million on an inventory build for the Caris Confirm MRD launch due before year-end.
Continue ReadingShow less
Caris Life Sciences delivered its strongest quarterly case volume on record in Q3 2026, powering revenue of $275.4 million and beating expectations. Molecular Profiling Services drove the gain on higher case volume and improved average selling prices.
GAAP diluted EPS came in at $0.05, beating expectations. Net income fell to $15.3 million from $24.3 million a year ago as operating expenses rose on headcount, research and development, and a national advertising campaign.
Sponsored
Free cash flow swung to negative $39.7 million in the quarter, a meaningful reversal driven partly by an inventory build tied to the upcoming Caris Confirm MRD assay. That product, a whole-genome, tumor-informed test for minimal residual disease, is targeted to launch before year-end. The company also expanded Caris Assure to cover therapeutic response monitoring, broadening the platform beyond its original therapy-selection use.
Management raised full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reaffirmed its clinical therapy selection volume growth target. With the Caris Confirm launch near and a share repurchase program in place, the question is whether the rollout converts volume momentum into improving cash flow.
Sources
Mentioned: CAI